Retevmo Approved for Treatment of Genetically-Mutated Lung and Thyroid Cancers
source: pixabay.com

Retevmo Approved for Treatment of Genetically-Mutated Lung and Thyroid Cancers

A recent BioSpace press release shares some exciting news for patients with non-small cell lung cancer, medullary thyroid cancer, and other thyroid cancers caused by RET gene mutations. Retevmo (selpercatinib) is the…

Continue Reading Retevmo Approved for Treatment of Genetically-Mutated Lung and Thyroid Cancers
Survivors of Thyroid Cancer Remain Concerned About Quality of Life and Treatment Effects, Study Says
Free-Photos / Pixabay

Survivors of Thyroid Cancer Remain Concerned About Quality of Life and Treatment Effects, Study Says

According to a story from Medscape, a recent study is highlighting the fact that many thyroid cancer survivors are still worried about cancer-related problems years after the conclusion of treatment.…

Continue Reading Survivors of Thyroid Cancer Remain Concerned About Quality of Life and Treatment Effects, Study Says
Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug
rawpixel / Pixabay

Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug

According to a press release from BeiGene, the Company and SpringWorks Therapeutics have launched MapKure, LLC — a new, jointly-operated venture owned by both partners. MapKure was founded to develop…

Continue Reading Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug
Second Ever Cancer Treatment Based on Biomarkers Approved by FDA
Source: Pixabay.com

Second Ever Cancer Treatment Based on Biomarkers Approved by FDA

On November 26, 2018, a new drug was given accelerated approval by the FDA. Not only that, but it was granted orphan drug designation and breakthrough therapy designation. The drug…

Continue Reading Second Ever Cancer Treatment Based on Biomarkers Approved by FDA
Breakthrough Therapy Awarded to a Drug For RET-Altered Thyroid and Non-Small Cell Lung Cancers
DarkoStojanovic / Pixabay

Breakthrough Therapy Awarded to a Drug For RET-Altered Thyroid and Non-Small Cell Lung Cancers

The United States FDA has awarded Breakthrough Therapy Designation to a drug called LOXO-292 for the treatment of RET-altered non-small cell lung cancer and thyroid cancer, in patients who meet…

Continue Reading Breakthrough Therapy Awarded to a Drug For RET-Altered Thyroid and Non-Small Cell Lung Cancers

Updated Results From Cancer Drug Trial Show Greater Improvements Than Previously Reported

According to a story from Reuters, the cancer drug developer Loxo Oncology recently released the latest results from the trial testing its investigational therapy LOXO-292. Preliminary results released about a…

Continue Reading Updated Results From Cancer Drug Trial Show Greater Improvements Than Previously Reported